ABBV · 10-Q · 2026Q2 · Full report

Gross Margin Drivers

AbbVie Inc. · 2026-08-03 · Importance 54 · Surprise 40 · In source text

Gross margin increased to $23.483 billion for the six months ended June 30, 2026 from $20.418 billion in the prior-year period. Gross margin as a percentage of net revenues increased for both the three and six months ended June 30, 2026. The improvement was driven by higher net revenues and lower fixed costs, primarily because amortization of intangible assets decreased. AbbVie reported $3.4 billion of intangible-asset amortization for the six months ended June 30, 2026.

Key facts

• Gross margin for the three months ended June 30, 2026: $12,699 million; for six months ended June 30, 2026: $23,483 million; gross margin as a percentage of net revenues increased compared to prior year primarily due to higher net revenues and lower fixed costs driven by decreased amortization of intangible assets. source
• For the three and six months ended June 30, 2026, the change in fair value reflected higher estimated Skyrizi sales, the passage of time and favorable clinical trial results for pipeline assets in combination with Skyrizi, partially offset by higher discount rates. source
• Amortization of intangible assets expense included in six months ended June 30, 2026: $3.4 billion. source

Impact estimates